Exploring the Psychophysics of Keratoconus Using the Moorfields Acuity Chart
NCT ID: NCT02429609
Last Updated: 2022-04-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
80 participants
INTERVENTIONAL
2015-04-15
2016-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Correlation Between Eye Rubbing and Keratoconus Severity in a Treatment-naive Keratoconic Population
NCT02883881
A Study to Test the Diagnostic Potential of Brillouin Microscopy for Corneal Ectasia
NCT02118922
Characterization of the Corneal Biomechanics of Patients Treated by Corneal Lenticule Extraction for Advanced Refractive Correction (CLEAR) to Correct Myopia
NCT04817592
CHOICE OF SUBJECTIVE OCULAR REFRACTION TECHNIQUE AND CORNEAL TOPOGRAPHY OF KERATOCONUS
NCT04174209
Development of a New Device and Method to Assess the Degree of Myopia and/or Astigmatism in Myopic People
NCT07297810
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
BASIC_SCIENCE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Keratoconic subjects
1. Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)
2. Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)
3. Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)
4. Anterior eye examination (approx. 4 minutes)
5. Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)
6. Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)
Two measurements of visual acuity will be made:
1. Standard ETDRS logMAR acuity measurement (5 minutes)
2. Vanishing Optotype logMAR acuity measurement (5 minutes)
Moorfields Acuity Chart
Healthy subjects
1. Short clinical interview (Questions pertaining to ocular and systemic health, medications, family history and date of birth). (approx. 2 minutes)
2. Visual acuity measurement using EDTRS chart at 4 m (approx. 4 minutes)
3. Refraction: retinoscopy and subjective, at 4m (approx. 10 minutes)
4. Anterior eye examination (approx. 4 minutes)
5. Fundus examination using binocular indirect ophthalmoscopy or a standard ophthalmoscope - to screen for eye disease that is likely to affect visual ability in this study. (approx. 5 minutes)
6. Corneal topography measurement with an Oculus Pentacam (Oculus Gmbh., Germany). (approx. 5 minutes)
Two measurements of visual acuity will be made:
1. Standard ETDRS logMAR acuity measurement (5 minutes)
2. Vanishing Optotype logMAR acuity measurement (5 minutes)
Moorfields Acuity Chart
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Moorfields Acuity Chart
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18-40 years.
* The presence of keratoconus in at least one eye.
* The absence of significant media opacities (e.g. cataract, corneal scarring).
* The absence of any other ocular pathology (e.g. glaucoma, diabetic retinopathy, uveitis).
* The absence of amblyopia in the test eye.
* No previous ocular surgery (e.g. corneal crosslinking, cataract surgery, etc.)
* Best corrected visual acuity better than or equal to 6/60 (1.0 logMAR).
* Pupil diameter ≥3 mm and ≤7 mm in normal room illumination.
Healthy subjects (30):
* Age 18-35 years.
* The absence of clinically significant keratoconus.
* The absence of significant media opacities. (e.g. cataract, corneal scarring).
* The absence of any other ocular pathology (e.g. glaucoma, diabetic retinopathy, uveitis).
* The absence of amblyopia in the test eye.
* No previous ocular surgery (e.g. corneal crosslinking, cataract surgery, etc.)
* Best corrected visual acuity better than or equal to 6/9 (0.1 logMAR).
* Pupil diameter ≥3 mm and ≤7 mm in normal room illumination.
18 Years
35 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Moorfields Eye Hospital NHS Foundation Trust
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ANDO1009
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.